{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:25:21Z","timestamp":1787775921481,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To explore the clinical value of transcatheter arterial chemoembolization (TACE) using a temperature-sensitive liquid embolic agent for the interventional treatment of primary hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The clinical data and follow-up results sourced from the First Affiliated Hospital of Fujian Medical University were retrospectively analyzed from February 2023 to May 2023. Clinical efficacy was assessed through follow-up imaging using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. In addition, adverse reactions and adverse events were observed and classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTC) version 3.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 11 patients analyzed in this study, a total of 41 lesions were identified. The average maximum diameter of the lesions was 3.55 \u00b1 1.88 cm (range: 1.70 cm\u20136.60 cm). One month postoperatively, the efficacy assessment revealed complete response (CR) in 1 case, partial response (PR) in 9 cases, stable disease (SD) in 1 case, and progression in 0 case. The objective response rate (CR + PR) was 90.91%, and the disease control rate (CR + PR + SD) was 100%. Postoperative adverse reactions were mostly of grade 1\u20132, including abdominal pain, bloating, fever, nausea, and vomiting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The use of temperature-sensitive liquid embolic agents loaded with lobaplatin for chemoembolization in the treatment of unresectable primary liver cancer is a safe and effective therapeutic modality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2250_24","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T02:04:03Z","timestamp":1746237843000},"page":"504-508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization"],"prefix":"10.4103","volume":"21","author":[{"given":"Shengyu","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Interventional Vascular, Jiangxi Chest Hospital, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Interventional Radiology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Interventional Radiology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"},{"name":"Department of Interventional Radiology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020:An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"R2-20250512","first-page":"1848","article-title":"Expert consensus on standardization of terminology used in clinical practice of TACE for hepatocellular carcinoma","volume":"101","author":"Ye","year":"2021","journal-title":"Chin Med J"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.4103\/jcrt.jcrt_2708_23","article-title":"Association of diabetes mellitus with long-term prognosis after ablation therapy for patients with hepatocellular carcinoma:A single-center cohort study","volume":"20","author":"Wang","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.4103\/jcrt.jcrt_1302_24","article-title":"Factors retarding enhanced recovery from thermal ablation of liver tumors:A single-center prospective study","volume":"20","author":"Zhang","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/gels3040036","article-title":"Poly(N-isopropylacrylamide) and copolymers:A review on recent progresses in biomedical applications","volume":"3","author":"Lanzalaco","year":"2017","journal-title":"Gels"},{"key":"R6-20250512","first-page":"592","article-title":"Clinical study of a novel temperature-sensitive embolic agent for arterial embolization in primary liver cancer","volume":"24","author":"Cao","year":"2015","journal-title":"J Interv Radiol"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0:Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:A multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"R11-20250512","first-page":"121","article-title":"Expert consensus on diagnosis and treatment of primary liver cancer in China (2019 Edition)","volume":"40","author":"Wu","year":"2020","journal-title":"Chin J Gen Surg"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12885-015-1480-x","article-title":"Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"15","author":"Kloeckner","year":"2015","journal-title":"BMC Cancer"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma:A meta-analysis","volume":"48","author":"Facciorusso","year":"2016","journal-title":"Dig Liver Dis"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10439-014-0972-1","article-title":"Therapeutic magnetic microcarriers guided by magnetic resonance navigation for enhanced liver chemoembilization:A design review","volume":"42","author":"Pouponneau","year":"2014","journal-title":"Ann Biomed Eng"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/1097-0142(19831215)52:12<2193::AID-CNCR2820521203>3.0.CO;2-R","article-title":"Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer","volume":"52","author":"Nakakuma","year":"1983","journal-title":"Cancer"},{"key":"R16-20250512","first-page":"333","article-title":"Recent advances in vascular interventional embolic materials for hepatocellular carcinoma treatment","volume":"31","author":"Liu","year":"2015","journal-title":"Chin J Clin Hepatol"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3760\/cma.j.issn.0366-6999.20131586","article-title":"Symptomatic pulmonary lipiodol embolism after transarterial chemoembolization for hepatic malignant tumor:Clinical presentation and chest imaging findings","volume":"127","author":"Xu","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R18-20250512","first-page":"135","article-title":"Cerebral lipiodol embolism following transcatheter arterial chemoembolization for hepatic tumors:Two case reports and literature review","volume":"20","author":"Liu","year":"2011","journal-title":"J Interv Radiol"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"576232","DOI":"10.3389\/fonc.2021.576232","article-title":"Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma:A meta-analysis","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"1079707","DOI":"10.3389\/fphar.2022.1079707","article-title":"The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer","volume":"13","author":"Bi","year":"2022","journal-title":"Front Pharmacol"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1039\/C8TB01078A","article-title":"Multifunctional smart hydrogels:Potential in tissue engineering and cancer therapy","volume":"6","author":"Li","year":"2018","journal-title":"J Mater Chem B"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.actbio.2016.10.001","article-title":"A stimuli responsive liposome loaded hydrogel provides flexible on-demand release of therapeutic agents","volume":"48","author":"O'Neill","year":"2017","journal-title":"Acta Biomater"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jvir.2021.02.018","article-title":"A water-based liquid embolic:Evaluation of its safety and efficacy in a rabbit kidney model","volume":"32","author":"Ganguli","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"R24-20250512","first-page":"1540","article-title":"Establishment of rabbit VX2 hepatocellular carcinoma model and interventional study of temperature-sensitive sustained-release embolic agents","volume":"21","author":"He","year":"2019","journal-title":"Chin J Exp Surg"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2250_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:45:00Z","timestamp":1787773500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2250_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2250_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-11-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}